<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002634</url>
  </required_header>
  <id_info>
    <org_study_id>EC2104220</org_study_id>
    <nct_id>NCT05002634</nct_id>
  </id_info>
  <brief_title>Safety of Undenatured Collagen Type II (UCII) Supplement in Healthy Volunteer</brief_title>
  <official_title>Safety of Undenatured Collagen Type II (UCII) Supplement in Healthy Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60&#xD;
      healthy volunteer. Liver function test, renal function test, and adverse event will be&#xD;
      assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60&#xD;
      healthy volunteer. The undenatured collagen type II (UCII) supplement 40 mg will be taken&#xD;
      once daily for 2 months. Liver function test, renal function test, and adverse event will be&#xD;
      assessed before and after taking for 1 and 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 5, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspartate aminotransferase value</measure>
    <time_frame>2 months</time_frame>
    <description>Aspartate aminotransferase value (U/L) in blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase value</measure>
    <time_frame>2 months</time_frame>
    <description>Alkaline phosphatase value (U/L) in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase value</measure>
    <time_frame>2 months</time_frame>
    <description>Alanine transaminase value(U/L) in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen value</measure>
    <time_frame>2 months</time_frame>
    <description>Blood urea nitrogen value (mg/dl) in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine value</measure>
    <time_frame>2 months</time_frame>
    <description>Creatinine value (mg/dl) in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>2 months</time_frame>
    <description>using questionnaire (Yes or No)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Health, Subjective</condition>
  <arm_group>
    <arm_group_label>undenatured collagen type II (UCII) supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>undenatured collagen type II (UCII) supplement</intervention_name>
    <description>The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.</description>
    <arm_group_label>undenatured collagen type II (UCII) supplement</arm_group_label>
    <other_name>UCII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-60 years&#xD;
&#xD;
          -  No taking collagen supplement more than 2 weeks&#xD;
&#xD;
          -  No collagen and protein allergy&#xD;
&#xD;
          -  No liver and renal disease&#xD;
&#xD;
          -  Have a willingness to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled disease&#xD;
&#xD;
          -  Have complication symptom during study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Cannot follow the protocol&#xD;
&#xD;
          -  During participated in other studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

